Bachem
More Content From Bachem
-
Navigating regulatory affairs challenges for successful drugs
Wed, 30 Oct, 2024 17:00 CET / 08:00 PST Virtual eventNews Releases Released on 10.01.2024
-
Visit Bachem at the Oligo Chemistry & Therapeutics Online Symposium 2024
Fri, 27 Sept, 2024News Releases Released on 08.23.2024
-
Visit Bachem at the Nordic Life Science Days 2024
Tue, 17 Sept, 2024 - Thu, 19, Sept 2024News Releases Released on 08.23.2024
-
Visit Bachem at the Boulder Peptide Symposium 2024
Mon, 16 Sept, 2024 - Thu, 19 Sept 2024News Releases Released on 08.23.2024
-
How to assess and reduce Nitrosamine Contamination Risks in Peptide APIs
...Sponsored Content Released on 07.30.2024
-
See Bachem at EPS - European Peptide Symposium
Sun, 25 Aug, 2024 - Thu, 29 Aug, 2024News Releases Released on 06.25.2024
-
See Bachem at Peptide Therapeutics Forum Basel
Thu, 22 Aug, 2024 - Fri, 23 Aug, 2024News Releases Released on 06.25.2024
-
See Bachem at Bio Asia-Taiwan 2024
Wed, 24 Jul, 2024 - Sun, 28 Jul, 2024News Releases Released on 06.25.2024
-
[WEBINAR] Mitigating supply chain risks in an age of disruption
Tuesday, June 11, 2024Sponsored Content Released on 05.23.2024
-
Bachem brings scientific expertise to Spring 2024 conferences
Bachem will use all three events to showcase its leading-edge capabilities as a peptide and oligonucleotide manufacturer.News Releases Released on 03.15.2024
-
No More DMF: Greener Solid-Phase Peptide Synthesis With Binary Solvents [WATCH ON-DEMAND]
Learn how the polarity and viscosity profiles of binary solvents can be used to predict their utility for producing different peptides by SPPS.Sponsored Content Released on 12.01.2023
-
[WEBINAR] Large-Scale TIDES Purification With MCSGP Under GMP
Join Bachem for a Virtual Event on Tuesday, December 5th, 2023.News Releases Released on 11.22.2023
-
Back to Stirred Vessels and on to Metric Tons of Oligonucleotides
Scientists seek to discover new production routes when manufacturing limits arise.Sponsored Content Released on 11.22.2023
-
[WEBINAR] Tag-assisted one-pot liquid-phase oligonucleotide synthesis
The webinar will take place on November 15, 2023 at 11:00 AM ET / 8:00 AM PT / 17:00 CETNews Releases Released on 11.08.2023
-
Leading the Octreotide Scale-Up - A Generics Case Study
Bachem Develops a Cost-Effective, Large-Batch Process for Octreotide Acetate SynthesisCase Studies Released on 11.08.2023
Related Content
-
Bachem reports excellent results for the first half-year 2021
Sales of CHF 500 million are now expected for the year 2021.
-
Bachem and Novo Nordisk Redesign SPPS for Green Chemistry
Replacing gold standard solvents to provide a greener alternative.
-
APIs
Propofol – A Bachem Success Story
The COVID-19 pandemic has rapidly expanded awareness of the API Propofol, produced by Bachem in Vionnaz.
-
Bachem News & Events
Learn more about what is happening at Bachem, what activities we have coming up, and what events you can meet us both virtually and in-person.
-
Bachem Capabilities to Address the New FDA Guideline for Synthetic Peptides
Scientific and regulatory challenges remain a big hurdle on the way to successful approval of generic drugs falling under this guideline.
-
Take Off With Bachem - A Step Into The Future
The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
-
APIs
Generic APIs Portfolio
With almost 50 years of expertise in peptide and small molecule synthesis, Bachem has an outstanding track record in large-scale manufacturing.
-
Customer Testimonial - Yuyu Pharma
Robert Yu, CEO of Yuyu Pharma, discussed his experience working with Bachem.
-
Customer Testimonial - Luye Pharma
Amy Zang, Head of Supply Chain at Luye Pharman spoke with us about her experience working with Bachem.
-
Biologics, Proteins, Vaccines | Breaking News | Capsules | Cold Chain Management | Drug Delivery | Formulation Development | Industry News | Solid Dosage/Semi-solids | Supply Chain | Vials
Catalent Awarded Grant Under Vaccine Research Consortium
Will evaluate Zydis Technology to develop thermo stable and cold-chain independent vaccines04.21.15
-
APIs | Chemistry | Process Development | Risk Management | Supply Chain
Pharmaceutical Fine Chemicals…Quo Vadit?
Captive and merchant demand estimated at $80 billion and growing 4-5% per annum.Dr. Enrico T. Polastro , Arthur D. Little 01.29.15
-
Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development
Biodel, Emergent BioSolutions Enter Glucagon Mfg. Pact
To provide fill/finish of commercial quantities for GEM deviceKristin Brooks 03.06.14
-
Bio News | Biosimilars | Promotions & Moves
